IFT20

Across TCGA pan-cancer cohorts, IFT20 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IFT20 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher IFT20 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFT20 expression acts as an unfavorable survival marker.

LSCC, CCRCC, and PDAC are the cancer types where IFT20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	13	view →
CCRCC	DFS	Median	III,IV	0.441	0.697	.017	9	view →
PDAC	OS	Tertile	All	0.667	0.943	.020	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IFT20–LSCC (DFS)

Open the LSCC breakdown →